The cycle-intelligent telemedicine
platform for women's healthcare.
platform for women's healthcare.
Sienna Evans
Founder & CEO · info@tryherx.com · tryherx.com
Women spend 25% more of their lives in poor health compared to men.
Average wait time for an accurate endometriosis diagnosis.
Closing the women's health gap represents $1 trillion annually by 2040.
Diagnostics, treatments, and medications are not fully optimized for female biology.
Cycle-linked symptoms are tracked casually, but never interpreted clinically.
Women's care is fragmented across apps, providers, pharmacies, and specialists.
The menstrual cycle is one of the most consistent biological signals in women's health, but today it is rarely connected to diagnosis, medication response, or care delivery.
| The Old Model | The HERx Model | |
|---|---|---|
| ReactiveTreats symptoms after they appear | → | PredictiveAnticipates needs before they escalate |
| EpisodicCare only at appointments | → | Continuous24/7 monitoring and guidance |
| Clinic-basedRequires physical presence | → | Mobile-firstCare wherever women are |
| FragmentedDisconnected providers | → | IntegratedOne ecosystem, one health record |
| GeneralizedPopulation-level protocols | → | PersonalizedIndividual cycle and health data |
AI-powered overview with personalized insights and actionable recommendations.
Advanced cycle tracking with hormone insights and AI recommendations.
AI that turns cycle and symptom data into clinically supervised actions: book, refill, refer, escalate, or educate.
Seamless end-to-end care from prescription approval to discreet delivery.
Personalized protocols with progress tracking and AI-driven adjustments.
Overlapping market segments, shown individually rather than summed. Source: Grand View Research.
Reproductive-age women across Florida (4.3M) and the Caribbean (4.5M) seeking cycle, weight, hormone, contraception, and telemedicine care.
Our 3-year target, built from the current waitlist, the existing Access Medical patient base, provider capacity, and paid acquisition.
Bahamas Pilot
50 patients × $399/mo × 12
Pre-launch demand
$309 gross profit / patient
50+ patients already on GLP-1 programs through HERx in The Bahamas. cycleLogic layers on top of an existing, paying cohort.
Active pharmacy licenses, provider agreements, and clinical ops inherited from Day 1. No new licensing required for Phase 1 Bahamas launch.
Scaling from 50 to 150 GLP-1 patients would generate approximately $718K ARR at the validated $399/month price point.
Active patients, pharmacy, and licensed providers remove the cold-start. Competitors would need 12–18 months and $3M+ to replicate.
Every interaction trains our models — more users → better predictions → higher retention. A flywheel competitors cannot shortcut.
Cycle tracking, telemedicine, GLP-1 care, pharmacy, and women's health support exist separately. HERx integrates them into one clinical operating system.
Validated Bahamas rate — already paying
Same-day consultations
cycleLogic intelligence + app access
Captured on every dispensed prescription via Access Medical's licensed pharmacy
Recurring subscription
Therapy access
Employer-sponsored plans
Licensing the Agentic Clinical Loop to other clinics
Healthcare entrepreneur and founder of Access Medical Bahamas, which grew from a COVID-19 testing lab into a network of clinics, pharmacy operations, and national healthcare services. Neuroscience background, MIT AI in Healthcare certification, and direct operating experience across clinical care, pharmacy, logistics, and patient acquisition.
Board-certified OB/GYN (DO, FACOOG) with decades of experience in women's health and patient-centered care. Provides strategic clinical oversight, supports provider partnerships, and shapes a personalized, proactive approach to hormonal health and preventive care across the Caribbean.
A dedicated pharmacist based in Nassau, Bahamas, passionate about advancing women's health through accessible, evidence-based care. Bridges the gap between pharmacy and preventive care to create personalized, supportive healthcare experiences for women.
Achieved at ~900 active monthly users
Blended across pharmacy and clinical services
Driven by U.S. expansion and B2B partnerships
| Year | Active Users | Blended ARPU | ARR |
|---|---|---|---|
| Year 1 | 2,500 | $76.35 | $2.29M |
| Year 2 | 7,500 | $76.35 | $6.87M |
| Year 3 | 20,000 | $76.35 | $18.32M |
| Year 4 | 45,000 | $76.35 | $41.23M |
| Year 5 | 75,000 | $76.35 | $68.71M |
AI models, app infrastructure, and EMR integration
Florida clinic launch and specialized provider hiring
Patient acquisition campaigns and B2B sales initiatives
Regulatory compliance and cross-border logistics
50 active GLP-1 Beta patients in The Bahamas, proving immediate willingness to pay for specialized care.
10,000 app waitlist signups, demonstrating clear market need and pent-up demand for the platform itself.
$309 gross profit per patient per month, operating with an exceptional 77% gross margin from day one.
If only 5% of the waitlist converts, HERx reaches 500 paying users. At $399/month, this represents $199,500 in monthly revenue and a $2.39M annualized revenue run rate.